ストックスクリーナーアプリを入手
38.32
0.29%
0.11
前日終値:
$38.21
開ける：
$37.9
24時間の取引高:
1.07M
Relative Volume:
0.41
時価総額：
$6.03B
収益：
$264.79M
当期純損益:
$-14.36M
株価収益率:
-348.36
EPS:
-0.11
ネットキャッシュフロー:
$-28.11M
1週間 パフォーマンス:
+6.50%
1か月 パフォーマンス:
-6.67%
6か月 パフォーマンス:
+60.07%
1年 パフォーマンス:
+177.28%
1日の値動き範囲:
$37.59
$38.92
1週間の範囲:
$35.29
$39.18
52週間の値動き範囲:
$12.93
$43.32
Tg Therapeutics Inc Stock (TGTX) Company Profile
名前
Tg Therapeutics Inc
セクター
電話
(212) 554-4484
住所
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
TGTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
38.32 | 6.03B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-29 | 開始されました | TD Cowen | Buy |
| 2023-08-02 | アップグレード | Goldman | Sell → Neutral |
| 2023-06-26 | 再開されました | Jefferies | Buy |
| 2022-05-20 | 開始されました | BofA Securities | Underperform |
| 2022-02-23 | 繰り返されました | B. Riley Securities | Buy |
| 2021-11-15 | ダウングレード | Goldman | Neutral → Sell |
| 2021-04-20 | 開始されました | Goldman | Neutral |
| 2021-04-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-09-01 | 開始されました | JP Morgan | Overweight |
| 2020-08-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-05 | 開始されました | Evercore ISI | Outperform |
| 2020-01-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-27 | 再開されました | B. Riley FBR | Buy |
| 2019-02-06 | 再開されました | Jefferies | Buy |
| 2018-09-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 再開されました | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 再開されました | H.C. Wainwright | Buy |
| 2017-04-25 | 開始されました | Jefferies | Buy |
| 2017-03-06 | 繰り返されました | FBR & Co. | Outperform |
| 2016-10-06 | 再開されました | Brean Capital | Buy |
| 2016-05-27 | 開始されました | SunTrust | Buy |
| 2015-12-01 | 開始されました | FBR Capital | Outperform |
| 2015-09-09 | 開始されました | Raymond James | Strong Buy |
| 2015-08-12 | 再開されました | H.C. Wainwright | Buy |
| 2015-06-19 | 繰り返されました | Brean Capital | Buy |
| 2014-12-11 | 繰り返されました | ROTH Capital | Buy |
| 2014-12-10 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Tg Therapeutics Inc (TGTX) 最新ニュース
Exploring US High Growth Tech Stocks - simplywall.st
TG Therapeutics: Progress In MS Tempered By High Expectations (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by LPL Financial LLC - MarketBeat
TG Therapeutics Announces Data Presentations for BRIUMVI in Mult - GuruFocus
TG Therapeutics shares data on multiple sclerosis treatment By Investing.com - Investing.com South Africa
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why - MSN
TG Therapeutics Shares Rise Almost 30% In 3 Months: Here's Why - Barchart.com
TGTX: Promising Short Squeeze Opportunity with Biopharma Focus - GuruFocus
TG Therapeutics (TGTX) Highlights New Research on BRIUMVI® for M - GuruFocus
TG Therapeutics (TGTX) Struggles with Low ROE Despite High Debt - GuruFocus
TG Therapeutics shares data on multiple sclerosis treatment - Investing.com
TG Therapeutics Announces Data Presentations for BRIUMVI in - GlobeNewswire
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential - Stock Titan
TG Therapeutics (TGTX) Shares Jump Amid Strong Briumvi Sales - GuruFocus
TG Therapeutics (TGTX) Highlights BRIUMVI® Data at Neurology Mee - GuruFocus
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet? - simplywall.st
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - The Manila Times
TG Therapeutics showcases BRIUMVI data at neurology meet - Investing.com
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile - Stock Titan
TG Therapeutics reports on MS treatment switch By Investing.com - Investing.com South Africa
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals - GlobeNewswire
TG Therapeutics reports on MS treatment switch - Investing.com
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short - Stock Titan
2seventy, TG, Springworks lead cancer index among Q1 market falls - BioWorld MedTech
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX) - The Globe and Mail
(TGTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
TGTX Gains as Roche's Ocrevus Fails in Phase 3 Trial; Impacting MS Market Dynamics - GuruFocus
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug - MSN
TG Therapeutics stock rises as Roche’s trial fails (TGTX) - Seeking Alpha
CRUCIAL INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm - ACCESS Newswire
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%? - Yahoo Finance
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - MSN
Why TG Therapeutics Stock Was Soaring This Week - MSN
Based On Its ROE, Is TG Therapeutics, Inc. (NASDAQ:TGTX) A High Quality Stock? - simplywall.st
(TGTX) Investment Analysis and Advice - Stock Traders Daily
TG Therapeutics stock soars to 52-week high of $43.03 By Investing.com - Investing.com India
TG Therapeutics stock soars to 52-week high of $43.03 - Investing.com
TG Therapeutics (TGTX) technical analysisTG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts - Yahoo Finance
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 By Investing.com - Investing.com Australia
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 - Investing.com India
Tg Therapeutics Inc (TGTX) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):